These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10215393)

  • 1. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical.
    Patterson C
    BMJ; 1999 Mar; 318(7186):810-11. PubMed ID: 10215393
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product.
    Bamber MG
    BMJ; 1999 Mar; 318(7186):810, author reply 810-11. PubMed ID: 10082724
    [No Abstract]   [Full Text] [Related]  

  • 3. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines.
    Ayres JG; Frost CD; Holmes WF; Williams DR; Ward SM
    BMJ; 1998 Oct; 317(7163):926-30. PubMed ID: 9756813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
    Forbes AL
    Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing surveillance for drug safety: surely we can do better.
    Griffin MR; Stein CM; Ray WA
    Clin Pharmacol Ther; 2004 Jun; 75(6):491-4. PubMed ID: 15179403
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical device epidemiology and surveillance: patient safety is the bottom line.
    Brown SL; Bright RA; Tavris DR
    Expert Rev Med Devices; 2004 Sep; 1(1):1-2. PubMed ID: 16293003
    [No Abstract]   [Full Text] [Related]  

  • 8. User reporting of medical device related incidents.
    Sievänen H
    Med Device Technol; 2003 May; 14(4):26-9. PubMed ID: 12774575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postmarketing surveillance studies in community pharmacies].
    Nieber K; Lehmacher W
    Med Monatsschr Pharm; 2009 Aug; 32(8):301-6. PubMed ID: 19777737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing drug surveillance: what it would take to make it work.
    CMAJ; 2001 Nov; 165(10):1293, 1295. PubMed ID: 11760966
    [No Abstract]   [Full Text] [Related]  

  • 11. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 12. Concerns with postmarketing surveillance.
    Norvell MJ; Anderson RJ
    Am J Hosp Pharm; 1984 Jan; 41(1):54, 56. PubMed ID: 6695933
    [No Abstract]   [Full Text] [Related]  

  • 13. The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
    Czeizel AE
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):635-9. PubMed ID: 11980253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EUROMEDIES concerted action outcomes.
    Vassilacopoulos G; Pangalos G; Doukidis G; Pramataris K; Pallikarakis N
    Stud Health Technol Inform; 1996; 28():175-217. PubMed ID: 10172835
    [No Abstract]   [Full Text] [Related]  

  • 15. ["There are clear criteria for product surveillance studies"].
    Throm S
    MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
    [No Abstract]   [Full Text] [Related]  

  • 16. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 17. Data quality in post-marketing surveillance.
    Girard M
    Adverse Drug React Acute Poisoning Rev; 1986; 5(2):87-95. PubMed ID: 3529880
    [No Abstract]   [Full Text] [Related]  

  • 18. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 19. European requirements for product returns.
    Donawa M
    Med Device Technol; 2005 Nov; 16(9):28-31. PubMed ID: 16438446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post-marketing surveillance].
    Roos JC
    Ned Tijdschr Geneeskd; 1996 Mar; 140(11):620-1. PubMed ID: 8649530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.